Platten 2_bearbeitet_bearbeitet_bearbeit

Prof. Dr. Michael Platten

Project C1

Chairman, Department of Neurology,

University Medical Center Mannheim, Heidelberg University &

CCU Neuroimmunology and Brain Tumor Immunology,

German Cancer Research Center Heidelberg

​

michael.platten(at)umm.de

Michael Platten is head of the CCU Neuroimmun-ology and Bain Tumor Immunology at DKFZ. He obtained his MD from the Department of Neuropathology at the University of Bonn and did his residency at the Department of Neurology, Tübingen University. Michael pursued postdoctoral fellowships in Neuroimmunology  at Stanford University and in Neurooncology at Tübingen University before becoming a Helmholtz Young Investigator at the Department of Neurology, University Hospital Heidelberg and German Cancer Research Center. Currently, he is the Chairman of the Department of Neurology at the Medical Faculty Mannheim, Heidelberg University and Head of the CCU Brain Tumor Immunology at DKFZ.

Qualifications and Scientific Curriculum

1998

2002-2004

2006

2010-2015

since 2013

since 2016

MD, University of Bonn, Germany

​

Postdoctoral Research Fellow, Stanford University, Stanford, USA

​

Board certified Neurologist

​

Associate Professor of Neuroimmunology, Heidelberg University, Germany

​

Head of Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Germany

​

Full Professor of Neurology and Chairman of the Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Germany

Selected publications

​

  1. Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pfleiderer K, Niesler B, von Deimling A, Opitz C, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M: Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun, 11:931, 2020.

  2. Sonner JK, Keil M, Falk-Paulsen M, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra SR, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus FC, Wick W, Bode HB, Rosenstiel P, Platten M: Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nat Commun, 10:4877, 2019.

  3. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger M, Harter P, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende CM, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suva M, Niemeyer BA, von Deimling A, Wick W, Platten M: Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. Nat Med, 24:1192-1203, 2018.

  4. Kirschbaum K, Sonner JK, Zeller MW, Deumelandt K, Bode J, Sharma R, Krüwel T, Fischer M, Hoffmann A, Costa da Silva M, Muckenthaler MU, Wick W, Tews B, Chen JW, Heiland S, Bendszus M, Platten M, Breckwoldt MO: In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. Proc Natl Acad Sci U S A, 113:13227-232, 2016.

  5. Bunse L, Schumacher T, Sahm S, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M: Proximity ligation assay evaluates presentation of mutant isocitrate dehydrogenase 1 in gliomas. J Clin Invest, 125:1-14, 2015.

  6. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M: A vaccine targeting mutant IDH1 induces antitumor immunity. Nature, 512:324-7, 2014.

  7. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W: mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A, 111:409-14, 2014.

  8. Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M: Endothelial protein kinase Cβ as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. P Proc Natl Acad Sci U S A, 110:14735-40, 2013.

  9. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M: NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Lancet Oncol, 13:707-15, 2012.

  10. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M: An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature, 478:197-203, 2011.